Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Re: Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Hopper JL, Baron JA.

J Natl Cancer Inst. 2003 Jul 2;95(13):1010-1; author reply 1012-3. No abstract available.

2.

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Narod SA, Dubé MP, Klijn J, Lubinski J, Lynch HT, Ghadirian P, Provencher D, Heimdal K, Moller P, Robson M, Offit K, Isaacs C, Weber B, Friedman E, Gershoni-Baruch R, Rennert G, Pasini B, Wagner T, Daly M, Garber JE, Neuhausen SL, Ainsworth P, Olsson H, Evans G, Osborne M, Couch F, Foulkes WD, Warner E, Kim-Sing C, Olopade O, Tung N, Saal HM, Weitzel J, Merajver S, Gauthier-Villars M, Jernstrom H, Sun P, Brunet JS.

J Natl Cancer Inst. 2002 Dec 4;94(23):1773-9.

3.

Re: Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

de Bock GH, Tollenaar RA, Papelard H, Vliet Vlieland TP, Devilee P, Cornelisse CJ, Vandenbroucke JP.

J Natl Cancer Inst. 2003 Jul 2;95(13):1011-2; author reply 1012-3. No abstract available.

4.

Re: Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Rookus MA, Brohet R, van Leeuwen FE.

J Natl Cancer Inst. 2003 Jul 2;95(13):1012. No abstract available.

5.

Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study.

Lee E, Ma H, McKean-Cowdin R, Van Den Berg D, Bernstein L, Henderson BE, Ursin G.

Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3170-8. doi: 10.1158/1055-9965.EPI-08-0396.

6.

Risk reduction works for BRCA mutation carriers--with heavy costs.

Vanchieri C.

J Natl Cancer Inst. 2005 Jul 20;97(14):1032-3. No abstract available.

7.

Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis.

Iodice S, Barile M, Rotmensz N, Feroce I, Bonanni B, Radice P, Bernard L, Maisonneuve P, Gandini S.

Eur J Cancer. 2010 Aug;46(12):2275-84. doi: 10.1016/j.ejca.2010.04.018. Review.

PMID:
20537530
8.

Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.

Rebbeck TR, Kauff ND, Domchek SM.

J Natl Cancer Inst. 2009 Jan 21;101(2):80-7. doi: 10.1093/jnci/djn442.

9.

Variation in breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Rebbeck TR, Domchek SM.

Breast Cancer Res. 2008;10(4):108. doi: 10.1186/bcr2115.

10.

Oral contraceptives and breast cancer risk.

Ansink AC, Burger CW.

J Clin Oncol. 2007 Nov 20;25(33):5327; author reply 5327-8. No abstract available.

PMID:
18024881
11.

BRCA1 and BRCA2 germ-line mutations and oral contraceptives: to use or not to use.

Grenader T, Peretz T, Lifchitz M, Shavit L.

Breast. 2005 Aug;14(4):264-8. Review.

PMID:
16085232
12.

[Are the hereditary forms of BRCA1 and BRCA2 breast cancer sensitive to estrogens?].

Pujol P, This P, Noruzinia M, Stoppa-Lyonnet D, Maudelonde T.

Bull Cancer. 2004 Jul-Aug;91(7-8):583-91. Review. French.

13.

Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Jernström H, Lubinski J, Lynch HT, Ghadirian P, Neuhausen S, Isaacs C, Weber BL, Horsman D, Rosen B, Foulkes WD, Friedman E, Gershoni-Baruch R, Ainsworth P, Daly M, Garber J, Olsson H, Sun P, Narod SA.

J Natl Cancer Inst. 2004 Jul 21;96(14):1094-8.

14.

Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1-2 mutation carriers.

Biglia N, Mariani L, Ponzone R, Sismondi P.

Maturitas. 2008 Jun 20;60(2):71-7. doi: 10.1016/j.maturitas.2008.03.004. No abstract available.

PMID:
18472232
15.

Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers.

Staton AD, Kurian AW, Cobb K, Mills MA, Ford JM.

Fam Cancer. 2008;7(2):179-86.

PMID:
18026853
16.

Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.

Walker LC, Waddell N, Ten Haaf A; kConFab Investigators., Grimmond S, Spurdle AB.

Breast Cancer Res Treat. 2008 Nov;112(2):229-36.

PMID:
18095154
17.

Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers.

Antoniou AC, Shenton A, Maher ER, Watson E, Woodward E, Lalloo F, Easton DF, Evans DG.

Breast Cancer Res. 2006;8(6):R72.

18.

Re: Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers.

Eisinger F, Huiart L.

J Natl Cancer Inst. 2009 Feb 18;101(4):277; author reply 277-8. doi: 10.1093/jnci/djn473. No abstract available.

19.

Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Kotsopoulos J, Lubinski J, Lynch HT, Neuhausen SL, Ghadirian P, Isaacs C, Weber B, Kim-Sing C, Foulkes WD, Gershoni-Baruch R, Ainsworth P, Friedman E, Daly M, Garber JE, Karlan B, Olopade OI, Tung N, Saal HM, Eisen A, Osborne M, Olsson H, Gilchrist D, Sun P, Narod SA.

Cancer Causes Control. 2005 Aug;16(6):667-74.

PMID:
16049805
20.

Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.

King MC, Marks JH, Mandell JB; New York Breast Cancer Study Group..

Science. 2003 Oct 24;302(5645):643-6.

Items per page

Supplemental Content

Support Center